Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications

Abstract

While levodopa, carbidopa, ascorbic acid solution (LCAS) therapy has been used in patients with advanced Parkinson's disease (PD) for many years, long-term follow-up data is scarce. The present study aimed to determine the long-term retention rate for LCAS therapy, and to identify the causes of LCAS therapy withdrawal. Our study included a series of 38 patients with PD (14 men and 24 women) who underwent LCAS treatment between 2011 and 2013 to alleviate motor complications that were not satisfactorily controlled by optimized conventional anti-parkinsonian treatment at the Seoul National University Hospital. All patients were admitted to educate them about and initiate LCAS treatment for 2–5 days, and were then followed up as outpatients. The mean follow-up duration was 12.8 months, and three main reasons for LCAS treatment discontinuation were worsening of wearing-off symptoms (8 patients), persistent dyskinesia (4 patients), and poor drug adherence (4 patients). Fourteen patients (36.8%) maintained the LCAS treatment after 12 months, and were categorized as the treatment-retention group. The mean percentage of on time without dyskinesia significantly increased from 33.6 ± 17.6% to 57.0 ± 27.7% after LCAS initiation (p = 0.016) in the treatment-retention group. Twelve patients (31.6%) were still receiving LCAS treatment after 30 months. LCAS treatment can be a non-device assisted therapeutic option for patients who have no access to advanced therapies such as deep brain stimulation and infusional treatments. © 2017 Elsevier B.V.